ArticleOncoTargets and therapy2018

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.

Bingkun Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.